{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T23:50:19Z","timestamp":1786492219056,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.vaccine.2018.02.022","type":"journal-article","created":{"date-parts":[[2018,3,18]],"date-time":"2018-03-18T15:26:16Z","timestamp":1521386776000},"page":"2213-2219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine"],"prefix":"10.1016","volume":"36","author":[{"given":"Sarah M.","family":"Tete","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5sne","family":"Jul-Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Rostami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turid Helen Felli","family":"Lunde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"S\u00f8land","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.02.022_b0005","unstructured":"Organization WH. Influenza (seasonal) Factsheet 211; 2014."},{"key":"10.1016\/j.vaccine.2018.02.022_b0010","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1128\/JVI.02205-08","article-title":"Proteolytic activation of the 1918 influenza virus hemagglutinin","volume":"83","author":"Chaipan","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.02.022_b0015","doi-asserted-by":"crossref","first-page":"13133","DOI":"10.1073\/pnas.1414070111","article-title":"Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans","volume":"111","author":"Ellebedy","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2018.02.022_b0020","doi-asserted-by":"crossref","first-page":"9047","DOI":"10.1073\/pnas.1118979109","article-title":"Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells","volume":"109","author":"Li","year":"2012","journal-title":"ProcNatlAcadSciUSA"},{"key":"10.1016\/j.vaccine.2018.02.022_b0025","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1084\/jem.20101352","article-title":"Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection","volume":"208","author":"Wrammert","year":"2011","journal-title":"JExpMed"},{"key":"10.1016\/j.vaccine.2018.02.022_b0030","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2018.02.022_b0035","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd4529","article-title":"Advances in the development of influenza virus vaccines","volume":"14","author":"Krammer","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2018.02.022_b0040","doi-asserted-by":"crossref","first-page":"e2975","DOI":"10.1371\/journal.pone.0002975","article-title":"Influence of prior influenza vaccination on antibody and B-cell responses","volume":"3","author":"Sasaki","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.02.022_b0045","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0264-410X(96)00058-8","article-title":"Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults","volume":"14","author":"Beyer","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.022_b0050","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/infdis\/jit825","article-title":"Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine","volume":"209","author":"Gaglani","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.022_b0055","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.vaccine.2010.10.038","article-title":"An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers","volume":"29","author":"Madhun","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.022_b0060","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/0264-410X(94)90334-4","article-title":"An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination","volume":"12","author":"Cox","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.022_b0065","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1128\/JVI.00641-13","article-title":"Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies","volume":"87","author":"Krammer","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.02.022_b0070","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.4049\/jimmunol.1201574","article-title":"Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies","volume":"190","author":"Jegaskanda","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.02.022_b0075","doi-asserted-by":"crossref","DOI":"10.1038\/npjvaccines.2016.1","article-title":"Dissecting the hemagglutinin head and stalk specific IgG antibody response in healthcare workers following pandemic H1N1 vaccination","volume":"1","author":"Tete","year":"2016","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2018.02.022_b0080","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00003495-200060010-00004","article-title":"Humoral immune response to influenza vaccination in patients from high risk groups","volume":"60","author":"Brydak","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2018.02.022_b0085","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1073\/pnas.1200039109","article-title":"Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses","volume":"109","author":"Pica","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2018.02.022_b0090","first-page":"2013","article-title":"Reduced hospital stay in influenza patients after mass vaccination during the, influenza pandemic in Norway","volume":"2013","author":"Mohn","year":"2009","journal-title":"J Vacc Vacc"},{"key":"10.1016\/j.vaccine.2018.02.022_b0095","doi-asserted-by":"crossref","unstructured":"Nachbagauer R, Choi A, Izikson R, Cox MM, Palese P, Krammer F. Age dependence and isotype specificity of influenza virus hemagglutinin stalk-reactive antibodies in humans. Mbio; 2016. p. 7.","DOI":"10.1128\/mBio.01996-15"},{"key":"10.1016\/j.vaccine.2018.02.022_b0100","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad0522","article-title":"Immune history profoundly affects broadly protective B cell responses to influenza","volume":"7","author":"Andrews","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2018.02.022_b0105","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1386-6532(01)00246-3","article-title":"The humoral response to live and inactivated influenza vaccines administered alone and in combination to young adults and elderly","volume":"24","author":"Stepanova","year":"2002","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2018.02.022_b0110","doi-asserted-by":"crossref","unstructured":"Nachbagauer R, Choi A, Izikson R, Cox MM, Palese P, Krammer F. Age dependence and isotype specificity of influenza virus hemagglutinin stalk-reactive antibodies in humans. mBio. 2016; 7: e01996-15.","DOI":"10.1128\/mBio.01996-15"},{"key":"10.1016\/j.vaccine.2018.02.022_b0115","doi-asserted-by":"crossref","first-page":"37229","DOI":"10.1038\/srep37229","article-title":"Investigating the effect of AS03 adjuvant on the plasma cell repertoire following pH1N1 influenza vaccination","volume":"6","author":"Galson","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2018.02.022_b0120","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1086\/652701","article-title":"Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1\/2 trial in adults","volume":"201","author":"Langley","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.022_b0125","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","article-title":"Adjuvant system AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity","volume":"29","author":"Morel","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.022_b0130","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo","volume":"20","author":"DiLillo","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2018.02.022_b0135","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiu334","article-title":"Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging influenza viruses","author":"Jegaskanda","year":"2014","journal-title":"J Infect Diseases"},{"key":"10.1016\/j.vaccine.2018.02.022_b0140","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.vaccine.2016.11.082","article-title":"Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection","volume":"35","author":"de Vries","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.022_b0145","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1158\/0008-5472.CAN-07-6297","article-title":"Engineered antibodies of IgG1\/IgG3 mixed isotype with enhanced cytotoxic activities","volume":"68","author":"Natsume","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2018.02.022_b0150","doi-asserted-by":"crossref","first-page":"e2574","DOI":"10.1371\/journal.pone.0002574","article-title":"Baseline levels of influenza-specific CD4 memory T-cells affect T-cell responses to influenza vaccines","volume":"3","author":"He","year":"2008","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2018.02.022_b0155","doi-asserted-by":"crossref","unstructured":"Zarnitsyna VI, Lavine J, Ellebedy A, Ahmed R, Antia R. Multi-epitope models explain how pre-existing antibodies affect the generation of broadly protective responses to influenza. Plos Pathog 2016; 12.","DOI":"10.1371\/journal.ppat.1005692"},{"key":"10.1016\/j.vaccine.2018.02.022_b0160","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1016\/j.vaccine.2015.08.065","article-title":"Relationship between haemagglutination inhibition titre and immunity to influenza in ferrets","volume":"33","author":"Wikramaratna","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.022_b0165","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s10875-010-9501-7","article-title":"Aging affects human B cell responses","volume":"31","author":"Frasca","year":"2011","journal-title":"J Clin Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18301968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18301968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:27:12Z","timestamp":1759400832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18301968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":33,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0264410X18301968"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.022","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}